IN THIS ISSUE

Every year, at-risk patients are encouraged to get the flu vaccine to prevent the spread of influenza and minimise the number of serious, or fatal, cases. The vaccine is commonly administered via intravenous injection, but in recent years researchers have been on the hunt for a needle-free solution. We chart the evolution of the flu vaccine to find out how practitioners are adapting to fight this virus hydra.

Also, we explore the challenges of developing drugs for children following the news that paediatric patients in the US are commonly prescribed drugs that have not been studied or approved for use in children, argue whether countries should repatriate API manufacturing to break up the China/India monopoly, and take a look at Ireland’s surging drug manufacturing industry and the interesting impact it appears to be having on local residents.

Plus, we examine the link between recurrent miscarriage and endometriosis, find out how PR spin doctors are helping Big Pharma companies to improve their public image, speak to the Gavi alliance about its role in immunising 300 million people by 2025, and investigate the problems with cancer trial design and administration.


Eloise McLennan, editor

Go to article: Home | Saving face: PR in pharma Go to article: In this issueGo to article: Emirates SkyCargoGo to article: ContentsGo to article: Hapa Company Insight Go to article: Owen MumfordGo to article: NewsGo to article: Dupont PharmaceuticalsGo to article: Accurate Biometrics Company Insight Go to article: Accurate BiometricsGo to article: The pharma industry briefingGo to article: Scandinavian Health Ltd.Go to article: Gerteis Company InsightGo to article: GerteisGo to article: Coughs and sneezes spread diseases: charting the development of flu vaccinesGo to article: Swiss WorldCargoGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: ‘Don’t put baby in the corner’: overcoming challenges in paediatric drug developmentGo to article: Qatar AirwaysGo to article: AtoZ-CRO Company InsightGo to article: AtoZ-CROGo to article: Debate: should countries bring critical drug production home?Go to article: AirBridgeCargo Company InsightGo to article: AirBridgeCargoGo to article: Capsugel Company Insight Go to article: Beyond Viagra Town: profiling the Irish pharma industryGo to article: Daiichi JitsugyoGo to article: TSS Company Insight Go to article: TSSGo to article: Recurrent miscarriage: could this devastating condition have a simple cure?Go to article: LB Bohle Company Insight Go to article: LB BohleGo to article: Public image limited: the role of PR in pharmaGo to article: Pharma Support Services Company InsightGo to article: Pharma Support ServicesGo to article: Q&A: Gavi alliance talks immunising 300 million people Go to article: Spirax Sarco Company Insight Go to article: Spirax SarcoGo to article: Bias remorse: are cancer drug trials clear enough on outcomes?Go to article: Zenatek Go to article: B&W TekGo to article: Deals in brief powered by GlobalDataGo to article: Centaur Clinical Insight Go to article: Centaur ClinicalGo to article: The key list powered by GlobalDataGo to article: AlpexGo to article: PfanstiehlGo to article: EventsGo to article: MimotopesGo to article: NymiGo to article: Next issue